Country Reports

This new issue of China Healthcare and Life Sciences Review (compiled in December 2019) provides a retrospective of the tremendous gains the Chinese healthcare industry made in 2019 while simultaneously anticipating the challenges and opportunities on the horizon in the new decade. From the steady national expansion of pilot regulatory reforms to the continuing exuberance…

See Full Report

With optimism and energy pervading the Chinese healthcare landscape, actors of all stripes see new potential and opportunities on the horizon. The heterogeneity of the Chinese market, with its 31 province-level entities offering a variety of market characteristics and needs; the waves of overseas returnees repatriating decades of experience in top pharma companies and biotechs,…

See Full Report

China is the country it is impossible to ignore and now accounts for a significant share of revenues for most major multinational pharmaceutical companies. Further, any firm sincerely committed to bringing treatments to the greatest number of patients has to be active in China, whose population of 1.3 billion people makes up nearly a fifth…

See Full Report
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here